Raiffeisen Bank International AG Boosts Stake in Stryker Corporation $SYK

Raiffeisen Bank International AG boosted its holdings in Stryker Corporation (NYSE:SYK) by 2.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 88,280 shares of the medical technology company’s stock after acquiring an additional 2,388 shares during the quarter. Raiffeisen Bank International AG’s holdings in Stryker were worth $32,653,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Bridgewater Advisors Inc. lifted its stake in shares of Stryker by 4.4% in the third quarter. Bridgewater Advisors Inc. now owns 1,944 shares of the medical technology company’s stock valued at $719,000 after purchasing an additional 82 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Stryker during the third quarter worth $741,000. Marshall & Sterling Wealth Advisors Inc. grew its holdings in Stryker by 25.5% in the third quarter. Marshall & Sterling Wealth Advisors Inc. now owns 639 shares of the medical technology company’s stock valued at $230,000 after purchasing an additional 130 shares during the last quarter. Fiera Capital Corp raised its stake in shares of Stryker by 24.5% during the 3rd quarter. Fiera Capital Corp now owns 28,828 shares of the medical technology company’s stock worth $10,657,000 after buying an additional 5,667 shares during the last quarter. Finally, Burling Wealth Partners LLC boosted its position in shares of Stryker by 34.6% in the 3rd quarter. Burling Wealth Partners LLC now owns 11,743 shares of the medical technology company’s stock worth $4,341,000 after buying an additional 3,021 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Up 2.0%

SYK stock opened at $380.15 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87. The business has a fifty day simple moving average of $360.05 and a 200-day simple moving average of $368.95. The company has a market cap of $145.48 billion, a price-to-earnings ratio of 45.26, a PEG ratio of 2.18 and a beta of 0.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same period last year, the business posted $4.01 EPS. The company’s revenue was up 11.4% on a year-over-year basis. On average, equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is 41.90%.

Analysts Set New Price Targets

A number of brokerages have issued reports on SYK. Sanford C. Bernstein lifted their target price on shares of Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Evercore set a $390.00 price objective on shares of Stryker in a research note on Monday, January 5th. Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research note on Friday, January 30th. BTIG Research raised their price target on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Finally, Raymond James Financial raised Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a report on Tuesday, January 6th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $426.94.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.